BioSpace News Archive

Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, will announce its results for the full year ended 31 December 2018 on Wednesday 27 February.

Reston Hospital Center (RHC) announced it is the first facility in Virginia to earn The Joint Commission’s Gold Seal of Approval® for Advanced Certification for Total Hip and Total Knee Replacement.

Praluent® (alirocumab) continues to be available in the U.S.

Data recently published in Clinical Cancer Research demonstrate the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC).

Almac Sciences, a member of the Almac Group, has announced a collaboration with Science Exchange, the world’s leading R&D Services Management company.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Liberty Health Sciences Inc.

In response to the U.S. Senate’s rejection of the Born Alive Abortion Survivors Act, Family Research Council is launching a campaign to deliver thousands of baby hats to Speaker of the House Nancy Pelosi.

Pomerantz LLP is investigating claims on behalf of investors of Diplomat Pharmacy, Inc..

Neovasc Inc. announced that it has commenced a proposed underwritten public offering of common shares of the Company.

Intersect ENT, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018.